A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Trial of Bapineuzumab in Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E E4 Non-Carriers.
Phase of Trial: Phase III
Latest Information Update: 27 Jan 2016
At a glance
- Drugs Bapineuzumab (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Pfizer; Wyeth
- 31 Aug 2018 Biomarkers information updated
- 16 Aug 2012 Additional trial location (Wales) added as reported by United Kingdom Clinical Research Network. (Parent trial: 4367)
- 06 Aug 2012 Status changed from recruiting to discontinued.